Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
AbbVie secures exclusive option to acquire global rights to ALV003.

AbbVie and Alvine Pharmaceuticals announced that they have entered into a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in Phase 2 development. This collaboration builds on AbbVie’s expertise and leadership in the field of gastroenterology with its on-market products to treat Crohn’s disease, ulcerative colitis, and diseases associated with exocrine pancreatic insufficiency.

ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet. Data from a Phase 2a study reported at Digestive Disease Week (DDW) 2012, showed reduction of intestinal inflammation in patients exposed to gluten and treated with ALV003 compared to patients treated with placebo.

“Celiac disease is an area with significant unmet medical need,” said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie. “Patients who currently are unable to completely avoid gluten in their diets could potentially benefit from this promising investigational treatment. AbbVie has significant experience within immunology and gastroenterology and the exclusive option to acquire this asset complements AbbVie’s broad mid-stage pipeline.”

“A collaboration between Alvine and AbbVie combines our respective strengths and expertise in the development of what could become the first therapeutic option for this major unmet medical need,” said Abhay Joshi, Ph.D., president and chief executive officer, Alvine. “We are pleased to have an industry leader in gastroenterology as a collaborator, whose considerable global development reach can be focused on getting this novel therapy to more patients.”

Under the terms of the agreement, AbbVie will make an initial upfront payment of $70 million for an exclusive option to either acquire the assets relating to ALV003, or the equity of the company. Alvine will maintain responsibility for Phase 2 clinical development, and upon successful completion of the approximately 500 patient Phase 2b study, AbbVie may exercise its option for the agreed upon additional consideration. Alvine will also be entitled to receive a milestone payment upon AbbVie’s initiation of Phase 3 development. In collaboration with AbbVie Biotech Ventures, Inc., a subsidiary of AbbVie dedicated to making early investments in emerging biotech and pharmaceutical companies, AbbVie was an early investor in Alvine Pharmaceuticals.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MD Anderson, AbbVie Connect to Advance Cancer Immunotherapy
New ways to unleash the immune system's potential to fight cancer.
Thursday, January 28, 2016
AbbVie, Halozyme Collaborate
The partnership will focus on developing and commercializing products that combine AbbVie’s compounds with Halozyme’s ENHANZE™ drug delivery platform.
Thursday, June 04, 2015
AbbVie and Calico Announce a Novel Collaboration
Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer.
Thursday, September 11, 2014
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
New Compound Shows Promise in Treating Multiple Human Cancers
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of all cancers.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos